{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif2ln5fa5hdtzvbanjambsx3ehwzxjqyqa4snokgn454x4zpj55mu",
    "uri": "at://did:plc:xc32dedgv3ceunwz2nrseso4/app.bsky.feed.post/3mjngd4yvthl2"
  },
  "path": "/x/91415d9aba777235?ref=rss",
  "publishedAt": "2026-04-16T21:54:06.000Z",
  "site": "https://upstract.com",
  "textContent": "Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical studies, generating enough evidence to support FDA approvals for three of them so far. But a new analysis throws more cold water on the treatment approach after years of…",
  "title": "'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again"
}